Bayer has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Medrad Centargo CT Injection System.
The system is a multipatient injector that integrates with Bayer’s portfolio of products, especially in high-volume CT suites. It is designed to minimize preparation time to under two minutes, streamlines data entry, and features a piston-based technology that allows for features such as dual flow to deliver contrast and saline at the same time, the company said.
By integrating with Bayer’s portfolio of imaging and workflow solutions, the company added that healthcare providers can optimize contrast usage and enable connectivity to the modality worklist and scanner.
Sunnybrook Health Sciences Centre in Toronto, Canada was the first hospital in North America to install and integrate Bayer’s Medrad Centargo CT Injection System in both acute care and outpatient settings.
![Axial images from unenhanced calcium score cardiac CT (left) and curved planar reformation images from CT angiography (right) show that higher long-term exposure to air pollution is associated with greater coronary artery calcium and more obstructive coronary artery disease (CAD). Top row: Images in a 68-year-old male patient with higher 10-year mean ambient air pollution exposure (7.9 μg/m3 for particulate matter measuring ≤2.5 μm in diameter [PM2.5] and 17.4 parts per billion [ppb] for NO2) with extensive CAD (coronary artery calcium score [CACS] >1,000 and obstructive CAD [≥70% diameter stenosis]). Bottom row: Images in a 57-year-old female patient with lower 10-year mean ambient air pollution exposure (6.3 μg/m3 for PM2.5 and 4.6 ppb for NO2) with no CAD (CACS = 0 and no obstructive stenosis).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/06/hanneman.r6SMLzkezo.png?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
